Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$17.78MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ryan J. Watts
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 503
- Beta
- 1.08
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 2.70
Financials
Revenue
$17.78M+2673.5%Net Income
$70.13MEBITDA
$73.70MFree Cash Flow
$-118.45MEPS (diluted)
$0.37Shares Outstanding (diluted)
192.08M+2030.1%Operating Expenses
$143.59MCash & Debt
$516.20MReturn of Capital
$0.00Revenue by Segment (annual)
$3.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-512.54M | $-2.97 |
| 2024 | $0.00 | $-422.77M | $-2.57 |
| 2023 | $330.53M | $-145.22M | $-1.06 |
| 2022 | $108.46M | $-325.99M | $-2.60 |
| 2021 | $48.66M | $-290.58M | $-2.39 |
| 2020 | $335.66M | $71.14M | $0.65 |
| 2019 | $26.68M | $-197.61M | $-2.07 |
| 2018 | $129.16M | $-36.24M | $-0.39 |
| 2017 | $0.00 | $-88.19M | $-5.89 |
| 2016 | $0.00 | $-86.65M | $-13.49 |
| 2015 | $0.00 | $-16.79M | $-5.58 |
Valuation
DNLIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (14)
- Newsseekingalpha.com·5d ago·Positive
Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·9d ago·Positive
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·9d ago·Positive
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy) I initiate Denali Therapeutics at Buy, as the Avlayah launch has validated the TransportVehicle platform and turned DNLI into a commercial-stage story. Q3 Avlayah sales of $17.8M crushed the $10-12M guide, and Q4 guidance of $30-32M implies 65%+ sequential growth. DNL126 in Sanfilippo A is heading toward a 2027 accelerated-approval BLA and reuses the Avlayah commercial playbook almost one-for-one.
View source ↗ - Newsmarketbeat.com·9d ago·Neutral
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near Denali Therapeutics NASDAQ: DNLI is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe disease and Alzheimer's disease.
View source ↗ - Newszacks.com·17d ago·Positive
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Neutral
Denali Therapeutics Q3 Earnings Call Highlights Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participants to commercial therapy supported a faster-than-expected launch.
View source ↗ - Newszacks.com·19d ago·Neutral
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.
View source ↗ - Newsglobenewswire.com·23d ago·Negative
… for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation. AVLAYAH is the first biologic approved by the U.S. Food and Drug Administration (FDA) that is specifically designed to cross the blood-brain barrier and reach the whole body, includin…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·94d ago·Positive
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
View source ↗ - Newsseekingalpha.com·95d ago·Positive
Denali Therapeutics: Bullish On Avlayah And Their Prospects AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. However, AVLAYAH's US label limits its near-term potential. Zafinofusp alfa and four TV-enabled 2027 readouts provide meaningful pipeline upside beyond AVLAYAH.
View source ↗ - Newsseekingalpha.com·101d ago·Positive
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodege…
View source ↗ - Newsgurufocus.com·104d ago·Negative
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.61 per share
Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.37 vs $-0.27beat
- Thu, Aug 6$-0.68 vs $-0.51miss
- Thu, May 7$-0.69 vs $-0.73beat
- Thu, Feb 26$-0.73 vs $-0.75beat
- Thu, Nov 6$-0.74 vs $-0.76beat
- Mon, Aug 11$-0.72 vs $-0.74beat
Estimates and results for DNLI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DNLI officers and directors.
- Bought
- $23k
- Sold
- $10.9m
2 trades
20 trades
- Chin Peter Scottsold
- Thornberry Nancysold
- Thornberry Nancysold
- Schuth Alexander O.sold
- Schuth Alexander O.sold
- Watts Ryan J.sold
- Schuth Alexander O.sold
- Baker Bros. Advisors Lpbought
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DNLI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
